Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Quick look at the key results According to clinical trial investigators, orforglipron: Led to significant weight reduction across all dosing groups Showed greater effects at the highest dose levels Helped lower blood sugar in people with diabetes Supported modest improvements in blood pressure Demonstrated mainly mild to moderate side effects The trial results suggest that the once-daily pill performs competitively with early GLP-1 injection studies
Sarcopenic obesity is linked to worse clinical outcomes than sarcopenia or obesity alone in hospitalized older adults
It has also been found to support cardiovascular health and to improve aerobic capacity during exercise
Comment on impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record study
US$ 28.87
US$ 23.42
US$ 20.36
US$ 23.03
